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Background
To determine whether the growth of tumors is sustained
by the whole cancer cell population or it is maintained
only by small fraction of cancer initiating cells, has crucial
impact on the design of suitable therapies. That is why the
research on defining the subpopulation of cancer initiating
cancer stem cells (CSC) in solid tumors has come into
highlights.
Materials and methods
A complex panel assay at cellular and molecular levels has
been performed on primary and metastatic cancerous tis-
sue biopsies and peripheral blood of patients with malig-
nant melanomas (n = 153) (Ethycal permission: ETT
TUKEB 16462- 02/2010).
Results
Cell cultures grew out of the great majority of the starter
metastatic tissue specimen and cancer initiating cells could
be sorted (BD FACSAvia Sorter) by colocalized unique sia-
lilated glycosphingolipids and anti CD20 binding capacity.
Characteristic growth pattern, spheroid forming, CSC mar-
kers like CD133, Nestin, ABCB5, CD20 and unique GD3
gangliosides were found. Patients′ sera and selected
patients′ Epstein Barr Virus transformed cell supernatants
in bulk or after limiting dilution cloning were tested for
cancer binding by ELISA and immunofluorescence. Our
novel tumor infiltrating B cell antibody phage display tech-
nique and DNA sequence cluster analysis (Vector NTI
Advance 11, Bioedit 7.0, ClustalX2.0.11) resulted in some
antibody fragments, belonging to representative tumor
binding antibody variable region subgroups, with defined
silalilated glycosphingolipid specificity.
Conclusion
Our strategy enables the detection and characterization of
cancer stem cells in metastatic melanomas, with potential
diagnostic importance. The novel peripheral blood and
tumor infiltrating B cell antibody profile analysis proved to
be a useful asset to reveal anti tumor humoral immune
responsiveness and harness it by antibody engineering
technique for further diagnostic and therapeutic usage.
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